Document Detail


Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial.
MedLine Citation:
PMID:  21037490     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: We sought to obtain preliminary data regarding the efficacy of omega-3 fatty acids for major depressive disorder associated with the menopausal transition. Secondary outcomes were assessed for vasomotor symptoms (or hot flashes).
METHODS: After a single-blind placebo lead-in, participants received 8 weeks of treatment with open-label omega-3 fatty acid capsules (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d). The Montgomery-Asberg Depression Rating Scale (MADRS) was the primary outcome measure. Hot flashes were monitored prospectively using daily diaries and the Hot Flash Related Daily Interference Scale. Blood samples for plasma pretreatment and posttreatment essential fatty acid assays were obtained. Because of the small sample size, data were analyzed using nonparametric techniques.
RESULTS: Of 20 participants treated with omega-3 fatty acids, 19 (95%) completed the study. None discontinued because of adverse effects. The pretreatment and final mean MADRS scores were 24.2 and 10.7, respectively, reflecting a significant decrease in MADRS scores (P < 0.0001). The response rate was 70% (MADRS score decrease of ≥50%), and the remission rate was 45% (final MADRS score of ≤). Responders had significantly lower pretreatment docosahexaenoic acid levels than nonresponders did (P = 0.03). Hot flashes were present in 15 (75%) participants. Among those with hot flashes at baseline, the number of hot flashes per day improved significantly from baseline (P = 0.02) and Hot Flash Related Daily Interference Scale scores decreased significantly (P = 0.006).
CONCLUSIONS: These data support further study of omega-3 fatty acids for major depressive disorder and hot flashes in women during the menopausal transition.
Authors:
Marlene P Freeman; Joseph R Hibbeln; Michael Silver; April M Hirschberg; Betty Wang; Amy M Yule; Laura F Petrillo; Erica Pascuillo; Nicole I Economou; Hadine Joffe; Lee S Cohen
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Menopause (New York, N.Y.)     Volume:  18     ISSN:  1530-0374     ISO Abbreviation:  Menopause     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-23     Completed Date:  2011-06-09     Revised Date:  2014-01-16    
Medline Journal Info:
Nlm Unique ID:  9433353     Medline TA:  Menopause     Country:  United States    
Other Details:
Languages:  eng     Pagination:  279-84     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Depressive Disorder, Major / blood,  drug therapy*
Docosahexaenoic Acids / blood
Fatty Acids, Omega-3 / adverse effects,  therapeutic use*
Female
Hot Flashes / drug therapy
Humans
Menopause / psychology*
Middle Aged
Placebos
Psychiatric Status Rating Scales
Treatment Outcome
Grant Support
ID/Acronym/Agency:
ZIA AA000115-11/AA/NIAAA NIH HHS
Chemical
Reg. No./Substance:
0/Fatty Acids, Omega-3; 0/Placebos; 25167-62-8/Docosahexaenoic Acids
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in n...
Next Document:  Acetaminophen inhibits status epilepticus in cultured hippocampal neurons.